Bracco advances GMP facility for cell therapy manufacturing

Bracco has announced progress in the development of a Good Manufacturing Practice compliant facility dedicated to cell therapy production, reinforcing its commitment to advanced therapeutic solutions. The new site is designed to support the manufacturing of innovative cell based products, with a focus on ensuring high quality standards and scalability.

The facility will enable Bracco to strengthen its capabilities in regenerative medicine, an area of growing importance within the pharmaceutical and biotech sectors. By investing in specialised infrastructure, the company aims to accelerate the transition of cell therapies from research into clinical and commercial stages.

Equipped with advanced technologies and controlled environments, the site is expected to meet stringent regulatory requirements while supporting flexible production processes. This approach will allow Bracco to adapt to evolving therapeutic needs and collaborate with partners developing next generation treatments.

The move reflects a broader industry trend towards increased investment in cell and gene therapy manufacturing, as demand for personalised and precision medicines continues to rise. Bracco’s expansion positions the company to play a more active role in this rapidly developing field.